Frequently Asked Questions

Enbiosis SA develops Digital Twin & AI-powered, clinically validated nutraceutical formulations targeting the gut microbiome. Enbiosis SA brings those formulations to South African manufacturers and brand owners.

Enbiosis SA operates from Building B, Alenti Office Park, 457 Witherite Road, The Willows, Pretoria.

Most formulations start with an ingredient. Enbiosis SA starts with the biology. Our Digital Twin and AI engine models the gut microbiome, identifies the disrupted pathways, and works backwards to determine the precise food-grade inputs needed. The result is a formulation with a defined biological purpose, not a generic blend.

The gut microbiome is a community of trillions of microorganisms in the digestive system that influences metabolism, immune function, brain health, hormonal balance, and more.

The gut microbiome is one of the body’s most powerful regulatory systems. By targeting it, we can address health conditions across multiple body systems — from metabolic and brain health to immune function, skin, and eye health.

Yes. Diet, lifestyle, environment, and genetics all shape the gut microbiome differently across regions and populations. This means an ingredient that works well in one population may produce different results in another. Enbiosis SA uses computational modelling to account for this variability, designing formulations that work across diverse microbiome profiles rather than a single population average.

Our Digital Twin and AI engine runs simulations across thousands of real human microbiome profiles to identify which pathways are disrupted in a specific health condition, then works backwards to determine the most targeted food-grade ingredients.

An AI-powered tool that works backwards from a target metabolite to identify the minimal set of food-grade ingredients that gut bacteria can naturally convert into the required compounds.

A digital twin is a virtual model of the gut microbiome. Before we select a single ingredient, we run thousands of simulations inside this model to understand how different combinations will behave in the gut. This means every formulation we design has been tested computationally before it is tested clinically.

All ingredients are food-grade and permitted by EFSA and FDA.

Enbiosis SA’s technology is being validated in stages, with pilot studies completed across several health areas. A pilot study in dry eye showed improvement in tear production, while a separate pilot study in blood sugar control showed improvement in fasting glucose and HbA1c. Both are now progressing into randomised, placebo-controlled trials to confirm these early findings at a higher standard of evidence. Other formulations in the Enbiosis SA pipeline are at earlier stages of clinical development.

Enbiosis SA is conducting clinical studies across multiple health areas, including eye, gastrointestinal, metabolic, urological, dermatological, hormonal, and neurological health.

Enbiosis SA formulations support gut microbiome pathways associated with specific health areas. They are not intended to diagnose, treat, cure, or prevent any disease. Please consult a healthcare professional for personal health concerns.

Enbiosis SA supports gut microbiome pathways across a broad range of health areas — including metabolic, cognitive and mental, neurological, immune, cardiovascular, skin, and autoimmune — as well as wellness goals such as eye health, longevity, oral health, and hormonal balance.

Enbiosis SA has developed a clinically validated formulation targeting gut microbiome pathways associated with eye health and ocular surface health through the gut-eye axis.

Enbiosis SA has developed formulations targeting gut microbiome pathways associated with brain health and cognitive function through the gut-brain axis. Clinical research in this area is ongoing.

Enbiosis SA has developed formulations targeting gut microbiome pathways associated with skin barrier function and hydration. Clinical research in this area is ongoing.

Enbiosis SA formulations are compatible with capsules & powders, dairy & fermented products, functional foods, and functional beverages (wellness drinks, metabolic shots). Format compatibility is evaluated per formulation.

Enbiosis SA operates as a B2B company. Our formulations are available through industry partners. Get in touch with the Enbiosis SA team to find out more.

Efficacy timelines vary depending on the formulation and health area. For detailed information, please contact our team directly.

All Enbiosis SA ingredients are food-grade and permitted by EFSA and FDA.

Enbiosis SA is a formulation platform. Our blends vary from formulation to formulation, so we are unable to provide vegan, halal, or kosher declarations for individual blends. These certifications are managed through our licensing partners. For more information, please contact our team directly.

Enbiosis SA offers two partnership models: Formulation Licensing and Nutraceutical Sales. For detailed information, please get in touch or contact our team directly.

Through Enbiosis SA, licences are available across South Africa and the wider SADC region.

Yes. Exclusivity is available by formulation, product category, and territory.

Enbiosis SA formulations are available for licensing or as a premix for nutraceutical brands and functional food and beverage companies looking to expand their product portfolio. For partners seeking a finished product, our branded formulations (en-TEAR, en-MASCULINE, en-CLEAR and en-JOY&FIT) are available for distribution partnerships. Get in touch to explore the right option for your business.

Enbiosis SA’s technology is supported by multiple layers of scientific and regulatory validation. The platform has received the UK Tech Rocketship Award Gold, with research published in Q1 peer-reviewed journals. Formulations are built exclusively from EFSA and FDA permitted ingredients, manufactured to GMP standards, and supported by active patent applications.